Research Activity
BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure
Cognition Therapeutics’ Stock Plummets After Alzheimer’s Drug Misses Cognitive Endpoint
Cognition Therapeutics, Alzheimer’s disease, cognitive endpoint, stock decline, clinical trial
NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations
NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease
GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines
GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership
NewAmsterdam Achieves Success in First of Three Pivotal Cardio Studies
NewAmsterdam, pivotal studies, cardio class, pharmaceuticals, medical breakthrough
FDA Halts vTv Therapeutics’ Type-1 Diabetes Clinical Trial Due to Chromatographic Signal
vTv Therapeutics, FDA, clinical trial, type-1 diabetes, cadisegliatin, chromatographic signal, patient safety, glucokinase activator
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug
Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1
George Church’s GRObio Secures $60 Million to Advance Gout Treatment into Clinical Trials
GRObio, George Church, Gout Treatment, Clinical Trials, Biotech Funding